

Antimicrobial Use Data Collection and Report to OIE – Nigeria

Dooshima Kwange and Mwapu Ndahi
Department of Veterinary and Pest Control Services
Federal Ministry of Agriculture and Rural Development

Presented at the OIE Sub-Regional Workshop on the database on antimicrobial agents intended for use in animals in Eastern and Southern Africa, Mombasa, Kenya. 29 – 31 October 2019

Outline

- ⌘ Introduction
- ⌘ AMR at the Animal Human Interface
- ⌘ Legal Framework in Nigeria
- ⌘ Collation of AMU Data
- ⌘ Reports - Quantities of AMU in Animal (2014-2017)
- ⌘ Challenges
- ⌘ Way forward
- ⌘ Conclusion


Introduction

- ‡ AMR occurs naturally
- ‡ Drivers - aggravated by over and misuse of antibiotics or use of poor quality/falsified antimicrobials, use for growth promotion, lack of observance of withdrawal periods
- ‡ AMR is OH Issue – must be tackled at the human – animal – environment interface
- ‡ Consequences in Agriculture
 - ‡ Increased cost of production
 - ‡ Loss of animals
 - ‡ Transmission of resistant pathogens and low grade AM as residues to humans and environment

Introduction (contd)

- ⌘ The indiscriminate use of antimicrobials for the prevention and treatment of bacterial infection in animals is a common practice in Nigeria as in other developing countries.
- ⌘ The increasing use of antimicrobials in veterinary practice/livestock production results in increase of resistant bacteria in animals.
- ⌘ Antimicrobials are the most frequently detected chemical residues in food of animal origin in Nigeria
 - ⌘ majority of these are antimicrobials commonly used in veterinary practice and/or in animal feed
- ⌘ In 2050, Nigeria's population is estimated to reach 400million and this will put added pressure on livestock production culminating in increased interaction at the animal-human-environment interface

The Animal – Human Interface



AMR at the Human-Animal Interface

- ‡ Studies in Nigeria have shown appreciable levels of resistant organisms isolated from animal and animal products
- ‡ Antibiotic use in animals can have direct and indirect effects on human health through
 - ‡ contact with antibiotic-resistant bacteria from animals and the environment,
 - ‡ consumption of food contaminated with resistant organism and
 - ‡ antibiotic residues in animal products
- ‡ Low recovery of resistant organisms from wildlife points to antimicrobial use in agriculture and veterinary practices as the principal driver of resistance in animals

Legal Framework

- ⌘ Laws and regulations governing medicine use in human and animals
 - ⌘ Drugs and related products (registration) Decree No.19 of 1993
 - ⌘ Poisons and Pharmacy Act, Cap 366 of 1990
 - ⌘ Food and Drugs Act Cap 150 of 1990
 - ⌘ Counterfeit and Fake Drugs (miscellaneous provisions) Act, Cap 73 of 1990


Legal Framework Cont'd

- ⌘ The National Essential Drugs List (EDL)
- ⌘ Veterinary Surgeons Act CAP V3 LFN 2004 (as amended)
- ⌘ Animal Disease Control Act LFN 1988
- ⌘ Meat Law (1968)
- ⌘ Nigerian Veterinary Formulary 2018



Collation and Reporting of AMU Data in Animals

& OIE member countries have been mandated to contribute to the OIE global database on antimicrobial agents intended for use in animals



Report of Quantities of AMU in Animal

- ∞ Collation and analysis of AMU data in animals from 2014 to 2017
- ∞ Data used is the veterinary drugs import data obtained from the National Food and Drug Administration and Control (NAFDAC)
- ∞ OIE guidance and template is used for calculations and reporting
- ∞ As per OIE guidelines AMU/C data submitted is the amount of active ingredients of the products in Kilograms
- ∞ The antimicrobial agents are reported by the different classes
- ∞ Reports:
 - ↳ baseline data
 - ↳ Option 1 – overall amounts (therapeutic and growth promotion)

S/N	Class	Type
1	Tetracyclines	Oxytetracyclines
		Chlortetracycline
2	Fluoroquinolones	Enrofloxacin
		Ciprofloxacin
		Norfloxacin
3	Aminoglycosides	Gentamycin
4	Macrolides	Tylosin
5	Polypeptides	Colistin sulphate
6	Penicillin	Amoxicillin
7	Amphenicols	Florfenicol
8	Sulphurnamides	Sulphurnamides
9	Glycopeptide	Ancomycin


S/N	Combined antimicrobials	Type
1	Amoxycol	Amoxycillin and Colistin
2	Tylodox	Tylosin and Doxycycline
3	Doxygen	Doxycycline and Gentamycin
4	Doxytyl	Doxycycline and Tylosin
5	Intergendox	Doxycycline and Gentamycin
6	Amoxystin	Amoxycillin and Colistin
7	Dimoxican	Colistin sulphate and Amoxycillin trihydrate

S/N	Combined antimicrobials	Type
8	Koleridin	Oxytetracycline and Neomycin sulphate
9	Conflox	Enrofloxacin and Bromhexin
10	EST Mix	Erythromycin, sulfadiazine and trimethoprim
11	Ciprovet	Sulphur and Ciprofloxacin
12	Sulpha 3	Sulfathiazole, Sulfadimidine and Sulfamerazine
13	Amoxitin	Amoxicillin trihydrate
14	Colisultrix	Trimethoprim and Colistin sulphate
15	Trisulmix	Trimethoprim and Sulfamethioxine
16	Sulfavet	Sulphadimidine and Trimethoprim


Amount of AMU in KG for 2014-2017

S/N	Antimicrobial	2014 (Jun-Dec)	2015	2016	2017
1	Aggregated	188,339	190,219	-	-
2	Tetracyclines	8,147	168,880	154,433	297,776
3	Fluoroquinolones	5,115	3,146	13,520	3,152
4	Macrolides	3,349	9,798	107,775	11,790
5	Sulfonamides	1,060	687	6,635	11,592
6	Polypeptides	459	142,333	4,290	1,892
7	Amphenicols	268	658	-	-
8	Penicillins	193	-	6,569	3,624
9	Aminoglycosides	46	131	37,341	9,052
10	Glycopeptides	24	40	-	-
11	Pleuromutilins	-	-	2	-
12	Nitrofurantoin	-	-	243	-
	Total (Kg)	207,000	515,892	330,809	338,878

Antimicrobials intended for use in animals in Nigeria for 2015,2016 and 2017



Amount of antimicrobials in Nigeria for 2014 to 2017



Challenges

- ⌘ Lack of specific regulations - sales, prescription, monitoring of quantities used, AMR surveillance
- ⌘ Incomplete import data received
- ⌘ Paucity of data on
 - ⌘ Lack of data on mortalities due to AMR in animals
 - ⌘ No of farms, clinics, sales outlets etc
 - ⌘ Resistant pathogens, AMU and residue levels in products
 - ⌘ Pharmaceutical companies' involvement

Challenges

- ⌘ Use of antibiotic additives in feed and water
- ⌘ OTC purchases
- ⌘ Informal and illegal trade across borders
- ⌘ Internet sales
- ⌘ Circulation of substandard and falsified drugs and drugs whose active ingredient is unknown
- ⌘ Lack of surveillance and monitoring of use of antimicrobials and resistance trends
- ⌘ Inadequate veterinary supervision in prescription and administration of AMs



Challenges

- ⌘ Weak collaboration between the Veterinary products regulatory bodies (NAFDAC, VCN, VPCS)
- ⌘ Disconnect between academia, private and public VS
- ⌘ From talk to practice of OH collaboration of the animal, human and environment sector
- ⌘ Limited funding for implementation of the AH activities of NAP

Way Forward

- ⌘ Enactment of specific regulations for AMR and AMU prevention and control
- ⌘ Advocacy to policy makers
- ⌘ Creation of awareness and education of stakeholders
- ⌘ Responsible and prudent use of antimicrobials especially in food producing animals
- ⌘ Proper record keeping by clinician and farmers
- ⌘ Veterinary supervision (prescription and administration)
- ⌘ Active involvement of pharmaceutical companies

Way Forward

- ⌘ Use of other alternatives to antibiotics – probiotics
- ⌘ Vaccinations, biosecurity and good animal husbandry practices
- ⌘ Build capacity of personnel, diagnostic facilities and regulatory bodies
- ⌘ Research for new products
- ⌘ Diligent implementation of the NAP

Conclusion

- & It is evident that AMR is a problem in animal health
- & Analysis of data being generated should be used for advocacy and sensitization
- & Multi-sectoral Collaborations
- & Monitoring
- & Commendations/Incentives
- ²& Enforcement



Acknowledgements

- & OIE
- & FMARD
- & NAFDAC

WE NEED YOU

— TO HANDLE —
ANTIMICROBIALS
— WITH CARE —



Fight #AntiMicrobialResistance

- **Misuse and overuse of antimicrobials increase resistance risk**, endangering both animal and human health and welfare.
- **But you can help.** By acting prudently when using antimicrobials, you can preserve their efficacy for our future.



WORLD ORGANISATION FOR ANIMAL HEALTH
Protecting animals, preserving our future

